REMARKS

In response to the Office Action mailed October 19, 2005, applicants elect Group I. As requested, in Examiner's items 7-11 and 13, applicants elect the following species function.

Examiner's Item 7 eosinophil function: receptor internalization

Examiner's Item 8 location of transmigration: lung

Examiner's Item 9 eosinophil reduced in body part affected by allergy: lung

Examiner's Item 10 chemoattractant: eotaxin 1

Examiner's Item 11 route of administration: intranasal

Examiner's Item 13 negatively affected cytokine: eotaxin 1

All claims in Group I are readable on the elected species.

Applicants respectfully state that our records reflect that the undersigned representative had previously made an oral election of method claims 1-34 and 44-50 during a telephone conference with Examiner Galvaz on October 25, 2004. Please explain why applicants' previous election was not made of record.

The Amendment to the Specification is made in response to the official Communication dated October 25, 2005.

Figures 2A and 2B have been amended to correct inadvertent transposition between the Figure legends. No new matter has been added. A "Replacement Sheet" and an "Annotated Sheet Showing Changes" for Figures 2A-E are attached to this Amendment.

Applicants do not believe there is any fee due with this submission.

Should any fees or surcharges be deemed necessary, the Examiner has authorization to charge fees or credit any overpayment to Deposit Account No. 23-3000.

The Examiner is invited to telephone the undersigned attorney if there are any questions or issues.

Respectfully submitted, WOOD, HERRON & EVANS, L.L.P.

Beverly A. Lyman Reg. No. 41,961

Wood, Herron & Evans, L.L.P. 2700 Carew Tower Cincinnati, OH 45202 513 241-2324 513 421-7269 facsimile

IN THE DRAWINGS

Figures 2A and 2B are amended to accurately match the figure and label.

Attachments: One "Replacement Sheet" depicting Figs 2A-2E

One "Annotated Sheet Showing Changes"




FIG. 2E